CD8A and neoplasm: To demonstrate that the BAY-I treatment-induced anti-tumor immunity is CD8+ T cell-dependent, we crossed the Pten-null mice with CD8-KO mice44 and generated Pten-null;Cd8-KO double knockout mice.